Primary liver cancer
Conditions
Interventions
single arm:Camrelizumb
Sponsors
The Second Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. There are no gender limits for patients over 18 years old; 2. Subjects with primary liver cancer confirmed by histopathology or cytology or in accordance with the clinical diagnostic criteria in the diagnostic and therapeutic criteria for primary liver cancer (2019 Edition); 3. Subjects with measurable target lesions examined by CT or MRI, except those with adjuvant therapy; 4. Subjects with child Pugh score <= 9; 5. ECoG physical status score was 0 ~ 2 points; 6. Patients who voluntarily join the study, sign informed consent, have good compliance and cooperate with follow-up; 7. The researchers believe that treatment can benefit.
Exclusion criteria
Exclusion criteria: 1. Patients who have been proved to be allergic to the test drug and its excipients; 2. Patients with active immunodeficiency disease or history of organ transplantation; 3. Patients with heart clinical symptoms or diseases that are not well controlled, for example: (1) NYHA grade 2 and above heart failure (2) Unstable angina pectoris (3) Myocardial infarction occurred within 1 year; 4. Patients with previous and current history of pulmonary fibrosis, interstitial pneumonia and severe impairment of lung function; 5. Pregnant or lactating women; 6. According to the judgment of the researcher, the patients who are not suitable to be included in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mPFS;RFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events;ORR;DCR;DoR;OS; | — |
Countries
China
Contacts
Public ContactZhendong Chen
The Second Affiliated Hospital of Anhui Medical University
Outcome results
None listed